Enterome to present at upcoming investor conferences

Paris, France – July 1, 2021

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:

  • BTIG Virtual Biotechnology Conference: August 9-10
  • C. Wainwright 23rd Annual Global Investment Conference: September 13-14

Download the press release (.pdf format)

 

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex